JP2010519243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519243A5 JP2010519243A5 JP2009550278A JP2009550278A JP2010519243A5 JP 2010519243 A5 JP2010519243 A5 JP 2010519243A5 JP 2009550278 A JP2009550278 A JP 2009550278A JP 2009550278 A JP2009550278 A JP 2009550278A JP 2010519243 A5 JP2010519243 A5 JP 2010519243A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mixture
- hydroxy
- pharmaceutically acceptable
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 230000003287 optical Effects 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 13
- 239000011780 sodium chloride Substances 0.000 claims 13
- 239000002253 acid Substances 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- -1 6-chloro-pyridin-3-yl-methoxy, tetrahydropyran-4-yl -Methoxy, 2- (2-oxo-pyrrolidin-1-yl) -ethoxy, 5-chloro-pyridin-2-yloxy, 6-bromo-pyridin-3-yloxy, phenethyloxy, 2- (tetrahydropyran-4- yl) - ethoxy Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- YEPNVMNZWCKIJN-UHFFFAOYSA-N 3-(5-chloropyridin-2-yl)oxy-N-(5-hydroxy-2-adamantyl)benzamide Chemical compound C1C(O)(CC2C3)CC3CC1C2NC(=O)C(C=1)=CC=CC=1OC1=CC=C(Cl)C=N1 YEPNVMNZWCKIJN-UHFFFAOYSA-N 0.000 claims 1
- VUVNVAUYTRZHFE-UHFFFAOYSA-N 3-(6-bromopyridin-3-yl)oxy-N-(5-hydroxy-2-adamantyl)benzamide Chemical compound C1C(O)(CC2C3)CC3CC1C2NC(=O)C(C=1)=CC=CC=1OC1=CC=C(Br)N=C1 VUVNVAUYTRZHFE-UHFFFAOYSA-N 0.000 claims 1
- YFMLHHJRWSGUGZ-UHFFFAOYSA-N 3-[(4-fluorophenyl)methoxy]-N-(5-hydroxy-2-adamantyl)benzamide Chemical compound C1C(O)(CC2C3)CC3CC1C2NC(=O)C(C=1)=CC=CC=1OCC1=CC=C(F)C=C1 YFMLHHJRWSGUGZ-UHFFFAOYSA-N 0.000 claims 1
- MLWHXMCKLSZOFX-UHFFFAOYSA-N 3-[(6-chloropyridin-3-yl)methoxy]-N-(5-hydroxy-2-adamantyl)benzamide Chemical compound C1C(O)(CC2C3)CC3CC1C2NC(=O)C(C=1)=CC=CC=1OCC1=CC=C(Cl)N=C1 MLWHXMCKLSZOFX-UHFFFAOYSA-N 0.000 claims 1
- XKKQDGWFVQKADA-UHFFFAOYSA-N 3-[2-(1-cyclopropylsulfonylpiperidin-4-yl)ethoxy]-N-(5-hydroxy-2-adamantyl)benzamide Chemical compound C1C(O)(CC2C3)CC3CC1C2NC(=O)C(C=1)=CC=CC=1OCCC(CC1)CCN1S(=O)(=O)C1CC1 XKKQDGWFVQKADA-UHFFFAOYSA-N 0.000 claims 1
- KPPDHMJWRQYREA-UHFFFAOYSA-N 4-[2-[3-[(5-hydroxy-2-adamantyl)carbamoyl]phenoxy]ethyl]-N-propan-2-ylpiperidine-1-carboxamide Chemical compound C1CN(C(=O)NC(C)C)CCC1CCOC1=CC=CC(C(=O)NC2C3CC4CC2CC(O)(C4)C3)=C1 KPPDHMJWRQYREA-UHFFFAOYSA-N 0.000 claims 1
- VJPXSFZLJFYYMZ-UHFFFAOYSA-N N-(5-hydroxy-2-adamantyl)-3-(2-phenylethoxy)benzamide Chemical compound C1C(O)(CC2C3)CC3CC1C2NC(=O)C(C=1)=CC=CC=1OCCC1=CC=CC=C1 VJPXSFZLJFYYMZ-UHFFFAOYSA-N 0.000 claims 1
- OFPSNPGFCJOWJK-UHFFFAOYSA-N N-(5-hydroxy-2-adamantyl)-3-(oxan-4-ylmethoxy)benzamide Chemical compound C1C(O)(CC2C3)CC3CC1C2NC(=O)C(C=1)=CC=CC=1OCC1CCOCC1 OFPSNPGFCJOWJK-UHFFFAOYSA-N 0.000 claims 1
- YTGNEVUWIALTLZ-UHFFFAOYSA-N N-(5-hydroxy-2-adamantyl)-3-[2-(2-oxopyrrolidin-1-yl)ethoxy]benzamide Chemical compound C1C(O)(CC2C3)CC3CC1C2NC(=O)C(C=1)=CC=CC=1OCCN1CCCC1=O YTGNEVUWIALTLZ-UHFFFAOYSA-N 0.000 claims 1
- VJUHTHSMLUUMSJ-UHFFFAOYSA-N N-(5-hydroxy-2-adamantyl)-3-[2-(oxan-4-yl)ethoxy]benzamide Chemical compound C1C(O)(CC2C3)CC3CC1C2NC(=O)C(C=1)=CC=CC=1OCCC1CCOCC1 VJUHTHSMLUUMSJ-UHFFFAOYSA-N 0.000 claims 1
- RAFPKYQYYBNVIG-UHFFFAOYSA-N N-(5-hydroxy-2-adamantyl)-3-phenylmethoxybenzamide Chemical compound C1C(O)(CC2C3)CC3CC1C2NC(=O)C(C=1)=CC=CC=1OCC1=CC=CC=C1 RAFPKYQYYBNVIG-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
Claims (12)
- 一般式（Ｉ）：
Ｑは、ヒドロキシであり；
Ｒ４は、水素であり；
Ｒ５は、水素であり；そして
Ｙは、２−［１−（カルボン酸イソプロピルアミド）ピペリジン−４−イル］−エトキシ、６−クロロ−ピリジン−３−イル−メトキシ、テトラヒドロピラン−４−イル−メトキシ、２−（２−オキソ−ピロリジン−１−イル）−エトキシ、５−クロロ−ピリジン−２−イルオキシ、６−ブロモ−ピリジン−３−イルオキシ、フェネチルオキシ、２−（テトラヒドロピラン−４−イル）−エトキシ、ベンジルオキシ、２−（１−シクロプロパンスルホニル−ピペリジン−４−イル）−エトキシ及び４−フルオロベンジルオキシからなる群から選択される］の化合物、又はその医薬的に許容可能な酸若しくは塩基との塩、又は任意の光学異性体、若しくはラセミ混合物を含む光学異性体の混合物、又は任意の互変異性体。 - 前記化合物が、４−｛２−［３−（５−ヒドロキシ−アダマンタン−２−イルカルバモイル）−フェノキシ］−エチル｝−ピペリジン−１−カルボン酸イソプロピルアミド、又はその医薬的に許容可能な酸若しくは塩基との塩、又は任意の光学異性体、若しくはラセミ混合物を含む光学異性体の混合物、又は任意の互変異性体である、請求項１に記載の化合物。
- 前記化合物が、３−（６−クロロ−ピリジン−３−イルメトキシ）−Ｎ−（５−ヒドロキシ−アダマンタン−２−イル）−ベンズアミド、又はその医薬的に許容可能な酸若しくは塩基との塩、又は任意の光学異性体、若しくはラセミ混合物を含む光学異性体の混合物、又は任意の互変異性体である、請求項１に記載の化合物。
- 前記化合物が、Ｎ−（５−ヒドロキシ−アダマンタン−２−イル）−３−（テトラヒドロ−ピラン−４−イルメトキシ）−ベンズアミド、又はその医薬的に許容可能な酸若しくは塩基との塩、又は任意の光学異性体、若しくはラセミ混合物を含む光学異性体の混合物、又は任意の互変異性体である、請求項１に記載の化合物。
- 前記化合物が、Ｎ−（５−ヒドロキシ−アダマンタン−２−イル）−３−［２−（２−オキソ−ピロリジン−１−イル）−エトキシ］−ベンズアミド、又はその医薬的に許容可能な酸若しくは塩基との塩、又は任意の光学異性体、若しくはラセミ混合物を含む光学異性体の混合物、又は任意の互変異性体である、請求項１に記載の化合物。
- 前記化合物が、３−（５−クロロ−ピリジン−２−イルオキシ）−Ｎ−（５−ヒドロキシ−アダマンタン−２−イル）−ベンズアミド、又はその医薬的に許容可能な酸若しくは塩基との塩、又は任意の光学異性体、若しくはラセミ混合物を含む光学異性体の混合物、又は任意の互変異性体である、請求項１に記載の化合物。
- 前記化合物が、３−（６−ブロモ−ピリジン−３−イルオキシ）−Ｎ−（５−ヒドロキシ−アダマンタン−２−イル）−ベンズアミド、又はその医薬的に許容可能な酸若しくは塩基との塩、又は任意の光学異性体、若しくはラセミ混合物を含む光学異性体の混合物、又は任意の互変異性体である、請求項１に記載の化合物。
- 前記化合物が、Ｎ−（５−ヒドロキシ−アダマンタン−２−イル）−３−フェネチルオキシ−ベンズアミド、又はその医薬的に許容可能な酸若しくは塩基との塩、又は任意の光学異性体、若しくはラセミ混合物を含む光学異性体の混合物、又は任意の互変異性体である、請求項１に記載の化合物。
- 前記化合物が、Ｎ−（５−ヒドロキシ−アダマンタン−２−イル）−３−［２−（テトラヒドロ−ピラン−４−イル）−エトキシ］−ベンズアミド、又はその医薬的に許容可能な酸若しくは塩基との塩、又は任意の光学異性体、若しくはラセミ混合物を含む光学異性体の混合物、又は任意の互変異性体である、請求項１に記載の化合物。
- 前記化合物が、３−ベンジルオキシ−Ｎ−（５−ヒドロキシ−アダマンタン−２−イル）−ベンズアミド、又はその医薬的に許容可能な酸若しくは塩基との塩、又は任意の光学異性体、若しくはラセミ混合物を含む光学異性体の混合物、又は任意の互変異性体である、請求項１に記載の化合物。
- 前記化合物が、３−［２−（１−シクロプロパンスルホニル−ピペリジン−４−イル）−エトキシ］−Ｎ−（５−ヒドロキシ−アダマンタン−２−イル）−ベンズアミド、又はその医薬的に許容可能な酸若しくは塩基との塩、又は任意の光学異性体、若しくはラセミ混合物を含む光学異性体の混合物、又は任意の互変異性体である、請求項１に記載の化合物。
- 前記化合物が、３−（４−フルオロ−ベンジルオキシ）−Ｎ−（５−ヒドロキシ−アダマンタン−２−イル）−ベンズアミド、又はその医薬的に許容可能な酸若しくは塩基との塩、又は任意の光学異性体、若しくはラセミ混合物を含む光学異性体の混合物、又は任意の互変異性体である、請求項１に記載の化合物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07102956 | 2007-02-23 | ||
| EP07102956.5 | 2007-02-23 | ||
| PCT/EP2008/051971 WO2008101914A2 (en) | 2007-02-23 | 2008-02-19 | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010519243A JP2010519243A (ja) | 2010-06-03 |
| JP2010519243A5 true JP2010519243A5 (ja) | 2011-03-10 |
| JP5243455B2 JP5243455B2 (ja) | 2013-07-24 |
Family
ID=39401046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009550278A Expired - Fee Related JP5243455B2 (ja) | 2007-02-23 | 2008-02-19 | 新規化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8383820B2 (ja) |
| EP (1) | EP2150526B1 (ja) |
| JP (1) | JP5243455B2 (ja) |
| KR (1) | KR101487813B1 (ja) |
| CN (1) | CN101679217A (ja) |
| AU (1) | AU2008219326B2 (ja) |
| BR (1) | BRPI0806847A2 (ja) |
| CA (1) | CA2675669C (ja) |
| EA (1) | EA016951B1 (ja) |
| IL (1) | IL199853A (ja) |
| MX (1) | MX2009008228A (ja) |
| WO (1) | WO2008101914A2 (ja) |
| ZA (1) | ZA200904916B (ja) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008515956A (ja) * | 2004-10-12 | 2008-05-15 | ノボ ノルディスク アクティーゼルスカブ | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型活性スピロ化合物 |
| WO2007051811A2 (en) * | 2005-11-01 | 2007-05-10 | Transtech Pharma | Pharmaceutical use of substituted amides |
| EP1948190A2 (en) * | 2005-11-01 | 2008-07-30 | Transtech Pharma | Pharmaceutical use of substituted amides |
| JP2009530346A (ja) * | 2006-03-21 | 2009-08-27 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | メタボリックシンドロームの治療用のアダマンタン誘導体 |
| WO2007115935A1 (en) | 2006-04-07 | 2007-10-18 | High Point Pharmaceuticals, Llc | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
| JP2009539937A (ja) * | 2006-06-16 | 2009-11-19 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 置換型ピペリジンカルボキサミドの医薬的使用 |
| US8048908B2 (en) * | 2006-07-13 | 2011-11-01 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
| JP2010519240A (ja) * | 2007-02-23 | 2010-06-03 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての、ｎ−アダマンチルベンズアミド |
| JP2010519239A (ja) * | 2007-02-23 | 2010-06-03 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害因子としてのｎ−アドマンチルベンザミド |
| WO2008101907A2 (en) * | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
| AU2007349112A1 (en) * | 2007-03-09 | 2008-09-18 | High Point Pharmaceuticals, Llc | Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors |
| JP2010522766A (ja) * | 2007-03-28 | 2010-07-08 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | １１ベータ−ｈｓｄ１活性化合物 |
| EP2152081B1 (en) * | 2007-04-11 | 2012-10-24 | High Point Pharmaceuticals, LLC | Novel compounds |
| EP2150109B1 (en) * | 2007-04-24 | 2012-09-19 | High Point Pharmaceuticals, LLC | Pharmaceutical use of substituted amides |
| WO2010059618A1 (en) * | 2008-11-21 | 2010-05-27 | High Point Pharmaceuticals, Llc | Adamantyl benzamide compounds |
| EP2243479A3 (en) | 2009-04-20 | 2011-01-19 | Abbott Laboratories | Novel amide and amidine derivates and uses thereof |
| ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
| EP2500345B1 (en) * | 2009-11-11 | 2015-01-28 | Sumitomo Dainippon Pharma Co., Ltd. | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative |
| US8871208B2 (en) * | 2009-12-04 | 2014-10-28 | Abbvie Inc. | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| US8513430B2 (en) | 2010-07-27 | 2013-08-20 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators |
| US8895552B2 (en) | 2010-09-03 | 2014-11-25 | Sumitomo Dainippon Pharma Co., Ltd. | Cyclic amide derivative |
| KR101332805B1 (ko) | 2011-03-31 | 2013-11-27 | 한국화학연구원 | 아다만틸기를 갖는 설파마이드 유도체 및 이의 약제학적으로 허용 가능한 염 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN104529858A (zh) * | 2015-01-13 | 2015-04-22 | 佛山市赛维斯医药科技有限公司 | 含卤代金刚烷和酰胺类衍生物、其制备方法和用途 |
| CN104529856A (zh) * | 2015-01-13 | 2015-04-22 | 佛山市赛维斯医药科技有限公司 | 一种硝基金刚烷酰胺衍生物、其制备方法和用途 |
| CN104974084A (zh) * | 2015-07-19 | 2015-10-14 | 佛山市赛维斯医药科技有限公司 | 一类胺基二吡啶叔醇结构的11β-HSD1抑制剂及其用途 |
| CN104974080A (zh) * | 2015-07-19 | 2015-10-14 | 佛山市赛维斯医药科技有限公司 | 二吡啶叔醇结构的11β-HSD1抑制剂、制备方法及其用途 |
| CN110291383B (zh) * | 2017-02-23 | 2021-12-28 | 株式会社Ihi | Oh自由基检测探测器、oh自由基测定装置以及oh自由基测定方法 |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1025881B (de) | 1955-11-26 | 1958-03-13 | Bayer Ag | Verfahren zur Herstellung von Kondensationsprodukten |
| US2913454A (en) * | 1956-11-23 | 1959-11-17 | Schenley Ind Inc | Certain cycloalkanotriazoles, process and intermediates |
| US3723442A (en) * | 1970-12-31 | 1973-03-27 | Yoshitomi Pharmaceutical | 3-oxo-1-oxa-4,8-diazaspiro(4.5)decanes |
| US3784551A (en) * | 1971-07-08 | 1974-01-08 | Yoshitomi Pharmaceutical | 2-oxo-1,4-dioxa-8-azaspiro (4.5) decanes and related compounds |
| FR2456731A1 (fr) | 1979-05-16 | 1980-12-12 | Choay Sa | Nouveaux derives substitues d'ary |
| US4350696A (en) * | 1980-03-08 | 1982-09-21 | Pfizer Inc. | Imidazole derivatives, process for their preparation and pharmaceutical compositions thereof |
| AU557300B2 (en) * | 1982-03-16 | 1986-12-18 | Farmitalia Carlo Erba S.P.A. | Substituted 1h-pyrazolo(1,5-alpha)pyrimidines and processes for their preparation |
| DE3445377A1 (de) * | 1983-12-23 | 1985-07-04 | Sandoz-Patent-GmbH, 7850 Lörrach | Carbocylische und heterocyclische carbonsaeureester und -amide von ueberbrueckten und nicht ueberbrueckten cyclischen stickstoffhaltigen aminen oder alkoholen |
| US5283352A (en) * | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
| FI864875A0 (fi) * | 1986-11-28 | 1986-11-28 | Orion Yhtymae Oy | Nya farmakologiskt aktiva foereningar, dessa innehaollande kompositioner samt foerfarande och mellanprodukter foer anvaendning vid framstaellning av dessa. |
| YU213587A (en) * | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| US5750532A (en) * | 1986-12-10 | 1998-05-12 | Schering Corporation | Pharmaceutically active compounds |
| US5272167A (en) * | 1986-12-10 | 1993-12-21 | Schering Corporation | Pharmaceutically active compounds |
| US4851423A (en) * | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
| US5225402A (en) * | 1989-02-10 | 1993-07-06 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| GB8904174D0 (en) * | 1989-02-23 | 1989-04-05 | British Bio Technology | Compounds |
| US5169850A (en) * | 1990-01-22 | 1992-12-08 | American Cyanamid Company | N-(dialkylamino)methylene)-substituted pyrazolo(1,5-a)-pyrimidine-3-carboxamides and N-(dialkylamino)methylene-substituted-4,5-dihydropyrazolo-(1,5-a)-pyrimidine-3-carboxamides |
| US5290803A (en) * | 1990-02-12 | 1994-03-01 | The Center Of Innovative Technology | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood |
| US5705521A (en) * | 1990-02-12 | 1998-01-06 | The Center For Innovative Technology | Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors |
| US5122539A (en) * | 1990-02-12 | 1992-06-16 | Center For Innovative Technology | Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood |
| US5677330A (en) * | 1990-02-12 | 1997-10-14 | The Center For Innovative Technology | Medical uses of allosteric hemoglobin modifier compounds in patient care |
| US5648375A (en) * | 1990-02-12 | 1997-07-15 | Virginia Commonwealth University | Use of hydrophobic compounds and anesthetics in combination with allosteric hemoglobin modifiers |
| US5432191A (en) * | 1990-02-12 | 1995-07-11 | The Center For Innovative Technology | Allosteric hemoglobin modifiers to decrease oxygen affinity in blood |
| US5731454A (en) * | 1990-02-12 | 1998-03-24 | Virginia Commonwealth University | Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood |
| US5049695A (en) * | 1990-02-12 | 1991-09-17 | Center For Innovative Technology | Allosteric hemoglobin modifiers |
| US5382680A (en) * | 1990-12-07 | 1995-01-17 | The Center For Innovative Technology | Allosteric hemoglobin modifier compounds |
| US5591892A (en) * | 1990-02-12 | 1997-01-07 | Center For Innovative Technology | Allosteric modifiers of hemoglobin |
| US5872282A (en) * | 1990-12-07 | 1999-02-16 | Virginia Commonwealth University | Allosteric modifiers of hemoglobin |
| FR2677984B1 (fr) * | 1991-06-21 | 1994-02-25 | Elf Sanofi | Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant. |
| US5260325A (en) * | 1991-08-19 | 1993-11-09 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking tertiary amides |
| US5258407A (en) * | 1991-12-31 | 1993-11-02 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
| US5356904A (en) * | 1992-10-07 | 1994-10-18 | Merck & Co., Inc. | Carbostyril oxytocin receptor antagonists |
| US5932569A (en) * | 1992-12-04 | 1999-08-03 | Janssen Pharmaceutica, N.V. | Triazolobenzazepine derivatives |
| US5571813A (en) * | 1993-06-10 | 1996-11-05 | Beiersdorf-Lilly Gmbh | Fused pyrimidine compounds and their use as pharmaceuticals |
| US5395846A (en) * | 1993-06-25 | 1995-03-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors |
| FR2708608B1 (fr) * | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant. |
| ES2152989T3 (es) * | 1993-08-10 | 2001-02-16 | Black James Foundation | Ligandos para los receptores de gastrina y cck. |
| US5426105A (en) * | 1993-09-24 | 1995-06-20 | G.D. Searle & Co. | Conformationally restricted angiotensin II antagonists |
| US5674879A (en) * | 1993-09-24 | 1997-10-07 | G.D. Searle & Co. | Compositions including and methods of using conformationally restricted angiotensin II antagonist |
| TW279860B (ja) * | 1993-11-12 | 1996-07-01 | Ciba Geigy Ag | |
| DE4338784A1 (de) | 1993-11-12 | 1995-05-18 | Langhals Heinz | Perylen-3,4-dicarbonsäureimide - neue hoch lichtechte Fluoreszenzfarbstoffe |
| GB9409150D0 (en) * | 1994-05-09 | 1994-06-29 | Black James Foundation | Cck and gastrin receptor ligands |
| WO1995032949A1 (en) * | 1994-05-27 | 1995-12-07 | James Black Foundation Limited | Gastrin and cck antagonists |
| US5795907A (en) * | 1994-05-27 | 1998-08-18 | James Black Foundation Limited | Gastin and CCK receptor ligands |
| US6001879A (en) | 1995-08-30 | 1999-12-14 | Bayer Aktiengesellschaft | Acylaminosalicylic acid amides and their uses as pesticides |
| FR2741878B1 (fr) * | 1995-12-01 | 1998-01-09 | Cird Galderma | Composes biaromatiques portant un groupement adamantyl en ortho, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
| TW359669B (en) * | 1995-12-15 | 1999-06-01 | Otsuka Pharma Co Ltd | Benzazepine derivatives |
| US6124289A (en) * | 1996-07-24 | 2000-09-26 | Dupont Pharmaceuticals Co. | Azolo triazines and pyrimidines |
| AU738197C (en) * | 1997-04-22 | 2002-05-16 | Cocensys, Inc. | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof |
| US6506783B1 (en) * | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
| US6521641B1 (en) * | 1998-10-08 | 2003-02-18 | Allergan, Inc. | Male anti-fertility agents |
| US6541477B2 (en) * | 1999-08-27 | 2003-04-01 | Scios, Inc. | Inhibitors of p38-a kinase |
| US6479552B2 (en) * | 1999-09-23 | 2002-11-12 | G.D. Searle & Co. | Use of substituted N, N-disubstituted diamino compounds for inhibiting cholesteryl ester transfer protein activity |
| AUPQ309399A0 (en) | 1999-09-28 | 1999-10-21 | Fujisawa Pharmaceutical Co., Ltd. | Benzothiazoline derivatives |
| SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| US6482829B2 (en) * | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
| US6636947B1 (en) * | 2000-08-24 | 2003-10-21 | International Business Machines Corporation | Coherency for DMA read cached data |
| US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| CA2465326C (en) | 2001-11-01 | 2011-03-29 | Icagen, Inc. | Pyrazolopyrimidines for decreasing ion flow through a voltage-dependent sodium channel |
| JP2003286171A (ja) | 2002-03-28 | 2003-10-07 | Sumitomo Pharmaceut Co Ltd | Ｐａｒ阻害剤 |
| AU2003226149A1 (en) * | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Substituted aryl amides |
| AU2003250117B2 (en) * | 2002-07-29 | 2007-05-10 | F. Hoffmann-La Roche Ag | Novel benzodioxoles |
| US7186735B2 (en) * | 2002-08-07 | 2007-03-06 | Sanofi-Aventis Deutschland Gmbh | Acylated arylcycloalkylamines and their use as pharmaceuticals |
| DE60310991T2 (de) * | 2002-11-07 | 2007-10-18 | Merck & Co, Inc. | Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes |
| WO2004056744A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| TW200503994A (en) * | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| AU2004218456A1 (en) * | 2003-02-28 | 2004-09-16 | Encysive Pharmaceuticals Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists. |
| AU2004215481B2 (en) * | 2003-02-28 | 2010-11-11 | Teijin Pharma Limited | Pyrazolo(1,5-A)pyrimidine derivatives |
| US7320989B2 (en) * | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| US20060094699A1 (en) * | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
| EP1615667A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
| US7700583B2 (en) * | 2003-04-11 | 2010-04-20 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
| US7501405B2 (en) * | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
| JP2006522750A (ja) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法 |
| US20070270408A1 (en) * | 2003-04-11 | 2007-11-22 | Novo Nordisk A/S | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines |
| EP2239012A3 (en) * | 2003-04-11 | 2011-06-15 | High Point Pharmaceuticals, LLC | Substituted amide derivatives and pharmaceutical uses thereof |
| JP2006522747A (ja) * | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 縮合１，２，４−トリアゾールの薬学的使用 |
| US7915293B2 (en) * | 2003-05-30 | 2011-03-29 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| JP2007501789A (ja) * | 2003-08-07 | 2007-02-01 | メルク エンド カムパニー インコーポレーテッド | １１−β−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのピラゾールカルボキサミド |
| US7517900B2 (en) * | 2003-10-10 | 2009-04-14 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| US20050261302A1 (en) * | 2004-04-29 | 2005-11-24 | Hoff Ethan D | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application |
| WO2006016882A2 (en) * | 2004-07-08 | 2006-02-16 | Ndsu Research Foundation | Methods and materials for enhancing the effects of protein modulators |
| NZ553159A (en) * | 2004-08-30 | 2010-05-28 | Janssen Pharmaceutica Nv | N-Adamantan-2-yl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
| JP2008515956A (ja) * | 2004-10-12 | 2008-05-15 | ノボ ノルディスク アクティーゼルスカブ | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型活性スピロ化合物 |
| WO2006044645A2 (en) * | 2004-10-13 | 2006-04-27 | Adolor Corporation | Sulfamoyl benzamides and methods of their use |
| US7511175B2 (en) | 2005-01-05 | 2009-03-31 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| KR101302627B1 (ko) * | 2005-01-05 | 2013-09-10 | 아비에 인코포레이티드 | 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제 |
| TW200716576A (en) * | 2005-06-07 | 2007-05-01 | Shionogi & Co | Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| CN1736485A (zh) | 2005-06-29 | 2006-02-22 | 上海美迪西生物医药有限公司 | 香草醛受体激动剂用于制备抗阿尔茨海默病产品的用途 |
| WO2007051811A2 (en) * | 2005-11-01 | 2007-05-10 | Transtech Pharma | Pharmaceutical use of substituted amides |
| EP1948190A2 (en) * | 2005-11-01 | 2008-07-30 | Transtech Pharma | Pharmaceutical use of substituted amides |
| JP5089185B2 (ja) | 2006-02-02 | 2012-12-05 | 大塚製薬株式会社 | コラーゲン産生抑制剤。 |
| JP2009530346A (ja) * | 2006-03-21 | 2009-08-27 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | メタボリックシンドロームの治療用のアダマンタン誘導体 |
| WO2007115935A1 (en) * | 2006-04-07 | 2007-10-18 | High Point Pharmaceuticals, Llc | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
| JP2009539937A (ja) | 2006-06-16 | 2009-11-19 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 置換型ピペリジンカルボキサミドの医薬的使用 |
| EP1878721A1 (en) | 2006-07-13 | 2008-01-16 | Novo Nordisk A/S | 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| JP2010519239A (ja) * | 2007-02-23 | 2010-06-03 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害因子としてのｎ−アドマンチルベンザミド |
| JP2010519240A (ja) * | 2007-02-23 | 2010-06-03 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての、ｎ−アダマンチルベンズアミド |
| WO2008101907A2 (en) | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
| AU2007349112A1 (en) * | 2007-03-09 | 2008-09-18 | High Point Pharmaceuticals, Llc | Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors |
| JP2010522766A (ja) * | 2007-03-28 | 2010-07-08 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | １１ベータ−ｈｓｄ１活性化合物 |
| EP2152081B1 (en) * | 2007-04-11 | 2012-10-24 | High Point Pharmaceuticals, LLC | Novel compounds |
| EP2150109B1 (en) * | 2007-04-24 | 2012-09-19 | High Point Pharmaceuticals, LLC | Pharmaceutical use of substituted amides |
| WO2010059618A1 (en) * | 2008-11-21 | 2010-05-27 | High Point Pharmaceuticals, Llc | Adamantyl benzamide compounds |
-
2008
- 2008-02-19 WO PCT/EP2008/051971 patent/WO2008101914A2/en active Application Filing
- 2008-02-19 US US12/528,229 patent/US8383820B2/en active Active
- 2008-02-19 ZA ZA200904916A patent/ZA200904916B/xx unknown
- 2008-02-19 MX MX2009008228A patent/MX2009008228A/es active IP Right Grant
- 2008-02-19 EA EA200970791A patent/EA016951B1/ru not_active IP Right Cessation
- 2008-02-19 AU AU2008219326A patent/AU2008219326B2/en not_active Ceased
- 2008-02-19 KR KR1020097017160A patent/KR101487813B1/ko active IP Right Grant
- 2008-02-19 JP JP2009550278A patent/JP5243455B2/ja not_active Expired - Fee Related
- 2008-02-19 CN CN200880005896A patent/CN101679217A/zh active Pending
- 2008-02-19 BR BRPI0806847-0A patent/BRPI0806847A2/pt not_active IP Right Cessation
- 2008-02-19 EP EP08709090.8A patent/EP2150526B1/en active Active
- 2008-02-19 CA CA2675669A patent/CA2675669C/en not_active Expired - Fee Related
-
2009
- 2009-07-14 IL IL199853A patent/IL199853A/en active IP Right Grant
-
2013
- 2013-01-11 US US13/739,408 patent/US8809540B2/en not_active Expired - Fee Related
-
2014
- 2014-07-02 US US14/321,884 patent/US8907096B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010519243A5 (ja) | ||
| RU2011127232A (ru) | Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP4931775B2 (ja) | 芳香族化合物 | |
| JP2011518774A5 (ja) | ||
| RU2427573C2 (ru) | Новые производные бензимидазола в качестве ингибиторов ваниллоидного рецептора 1 (vr1) | |
| JP2010533722A5 (ja) | ||
| ATE518845T1 (de) | Optische isomere eines iloperidon-metaboliten | |
| JP2009521431A5 (ja) | ||
| JP2010514828A5 (ja) | ||
| JP2012510502A5 (ja) | ||
| RU2356893C2 (ru) | Ингибиторы фосфодиэстеразы 4 | |
| JP2009519965A5 (ja) | ||
| JP2013517283A5 (ja) | ||
| JP2004508356A5 (ja) | ||
| JP2011509916A5 (ja) | ||
| WO2006016637A1 (ja) | 新規環状アミノ安息香酸誘導体 | |
| CN1578767A (zh) | 哌啶－2－酮衍生化合物及包含其作为活性成分的药学组合物 | |
| JP2005527593A5 (ja) | ||
| JP2010526025A5 (ja) | ||
| JP2016514117A5 (ja) | ||
| JP2009543795A5 (ja) | ||
| CN101031541A (zh) | 4－氨基甲基苄脒衍生物及其作为因子Ⅷa抑制剂的用途 | |
| RU2014109853A (ru) | Соединения для связывания со специфическим для тромбоцитов гликопротеином iib/iiia и их применение для визуализации тромбов | |
| CA2598516A1 (en) | Benzisoxazole derivatives | |
| JP2011500694A5 (ja) |